Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Unlocking the Future of Medicine: An In-Depth Exploration of Pharmacogenomics
Mohamad-Ali Salloum, PharmD • December 9, 2023
Share
Understanding Pharmacogenomics:
The world of pharmacology is continually evolving, and one of the most exciting frontiers is Pharmacogenomics. Usually, we treat patients based on their clinical characteristics. But with pharmacogenomics, we take into consideration the genetic variability of drug metabolism and response within each person. This allows us to exactly treat what the patient is suffering from, and at the same time reduce some of the unwanted side effects in some cases.
What are the implications of PG in Pharmacy Practice?
1. Individualized Treatment Plans:
Warfarin, an anticoagulant, poses challenges due to its narrow therapeutic window. Pharmacogenomic testing can identify variations in genes like CYP2C9 and VKORC1, influencing an individual's response to warfarin. This genetic insight enables healthcare professionals to determine the most effective and safe dosage for each patient, reducing the risk of bleeding or clotting events.
2. Prevention of Adverse Reactions:
By identifying genetic factors that may contribute to adverse drug reactions, pharmacogenomics helps prevent unnecessary complications, enhancing patient safety. This proactive approach aligns with the core principle of pharmacy practice: first, do no harm.
3. Optimizing Drug Selection:
Understanding a patient's genetic profile enables pharmacists to choose medications with the highest likelihood of efficacy. This approach reduces the need for trial-and-error approaches, streamlining the medication selection process and enhancing overall patient care. This is important, especially in the time-sensitive cases of cancer patients where they require the most effective treatment as soon as possible to counteract the cancer invasion.
Challenges and Future Directions:
While the promise of Pharmacogenomics is undeniable, there are some challenges that stops it from being used as frequently as it should be such as:
- Cost,
- Accessibility,
- Need for the broader genetic databases.
I listed below some of the examples to help you understand how PharmacoGenomics can contribute to better management of the patient’s disease.
1. Warfarin Dosing:
Warfarin, an anticoagulant, poses challenges due to its narrow therapeutic window. Pharmacogenomic testing can identify variations in genes like CYP2C9 and VKORC1, influencing an individual's response to warfarin. This genetic insight enables healthcare professionals to determine the most effective and safe dosage for each patient, reducing the risk of bleeding or clotting events.
2. Clopidogrel Metabolism:
Clopidogrel, an antiplatelet medication, requires activation by the enzyme CYP2C19. Genetic variations in the CYP2C19 gene can lead to reduced drug activation, affecting the drug's effectiveness in preventing blood clots. Pharmacogenomic testing empowers clinicians to make informed decisions about alternative antiplatelet medications for individuals with specific genetic profiles, optimizing cardiovascular care.
3. Codeine Metabolism:
Codeine, an opioid analgesic, undergoes metabolism to its active form through the enzyme CYP2D6. Some individuals possess genetic variations that result in poor metabolism of codeine, leading to inadequate pain relief. Pharmacogenomics can identify patients who may require alternative pain management strategies, preventing ineffective treatment and potential adverse reactions.
4. Allopurinol and HLA-B Gene:
Allopurinol, used in the management of gout, is associated with a potentially severe adverse reaction known as Stevens-Johnson Syndrome (SJS). The risk of developing SJS is significantly increased in individuals with a specific variant of the HLA-B gene. Pharmacogenomic testing can identify patients at higher risk, allowing healthcare providers to consider alternative gout medications to minimize the risk of this life-threatening reaction.
Conclusion:
The journey into Pharmacogenomics is an ongoing exploration, and your role as future pharmacists is pivotal. With each step, you are not just studying pharmacology; you are becoming architects of a healthcare future that truly puts the patient at the center. Embrace the possibilities, navigate the challenges, and let the principles of Pharmacogenomics guide your path toward a future where the right drug, for the right patient, at the right time becomes more than a mantra—it becomes a reality.
References:
1. Johnson JA. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet. 2003;19(11):660-666.
2. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343-350.
3. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317-323.
4. Stanek EJ, Sanders CL, Taber KA, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012;91(3):450-458.
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
Boost your health with a simple 30‑minute morning walk backed by science—better heart health, mood, sleep, and energy.
References: Gunes IB, Gunes A. Association Between Eyelid Twitching and Digital Screen Time, Uncorrected Refractive Error, Intraocular Pressure, and Blood Electrolyte Imbalances. Cureus . 2024;16(9):e69249. Available from: https://www.cureus.com/articles/291035-association-between-eyelid-twitching-and-digital-screen-time-uncorrected-refractive-error-intraocular-pressure-and-blood-electrolyte-imbalances Banik R, Miller NR. Chronic myokymia limited to the eyelid is a benign condition. J Neuroophthalmol . 2004;24(4):290–2. Available from: https://scholars.mssm.edu/en/publications/chronic-myokymia-limited-to-the-eyelid-is-a-benign-condition-2 Hallett M. Blepharospasm: recent advances. Neurology . 2002;59(11):1759–60. Available from: https://europepmc.org/abstract/MED/12434791 Defazio G, Livrea P. Epidemiology of primary blepharospasm. Mov Disord . 2002;17(1):7–12. Available from: https://europepmc.org/article/MED/11835433 Zeppieri M, Ameer MA, Jahngir MU, Patel BC. Meige Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://europepmc.org/article/MED/30020730 Zhang Y, Adamec I, Habek M. Superior oblique myokymia: a meta-analysis. J Ophthalmol . 2018;2018:7290547. Available from: https://doi.org/10.1155/2018/7290547 Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev . 2020;11:CD004900. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004900.pub2/abstract Khalkhali M. Topiramate-induced persistent eyelid myokymia. Case Rep Psychiatry . 2016;2016:7901085. Available from: https://europepmc.org/articles/PMC4886081/
References: Sen A, Tai XY. Sleep duration and executive function in adults. Curr Neurol Neurosci Rep. 2023;23:801–813. [link.springer.com] Nature Research Intelligence. Sleep deprivation and cognitive performance. Nature Portfolio. 2023. Available from: https://www.nature.com/… [nature.com] Skourti E, Simos P, Zampetakis A, et al. Long-term associations between objective sleep and verbal memory performance. Front Neurosci. 2023;17:1265016. [frontiersin.org] Hauglund NL, Andersen M, Tokarska K, et al. Norepinephrine‑mediated slow vasomotion drives glymphatic clearance during sleep. Cell. 2025;188(3):606‑622.e17. [cell.com] Shirolapov IV, Zakharov AV, Smirnova DA, et al. The role of the glymphatic clearance system in sleep–wake interactions and neurodegeneration. Neurosci Behav Physiol. 2024;54:199–204. [link.springer.com] Kong Y, Yu B, Guan G, et al. Effects of sleep deprivation on sports performance: a systematic review and meta-analysis. Front Physiol. 2025;16:1544286. [frontiersin.org] Gong M, Sun M, Sun Y, et al. Effects of acute sleep deprivation on sporting performance in athletes. Nat Sci Sleep. 2024;16:—. [tandfonline.com] Dean B, Hartmann T, Wingfield G, et al. Sleep restriction between consecutive days of exercise impairs cycling performance. J Sleep Res. 2023;32(3):e13857. [onlinelibr....wiley.com] Mah CD, Mah KE, Kezirian EJ, Dement WC. The effects of sleep extension on athletic performance in collegiate basketball players. Sleep. 2011;34(7):943–950. [psycnet.apa.org] Cunha LA, Costa JA, Marques EA, et al. Impact of sleep interventions on athletic performance: a systematic review. Sports Med Open. 2023;9:58. [link.springer.com] Teece AR, Beaven CM, Argus CK, et al. Daytime naps improve afternoon power and perceptual measures in elite rugby union athletes. Sleep. 2023;46(12):zsad133. [academic.oup.com] Mesas AE, Núñez de Arenas-Arroyo S, Martinez-Vizcaino V, et al. Daytime napping and cognitive/physical sport performance: meta-analysis of RCTs. Br J Sports Med. 2023;57(7):417–27. [bjsm.bmj.com] Haines Roberts SS, Teo WP, Warmington SA. Effects of training and competition on the sleep of elite athletes. Br J Sports Med. 2019;53(8):513–522. [bjsm.bmj.com] Walsh NP, Halson SL, Sargent C, et al. Sleep and the athlete: 2021 expert consensus recommendations. Br J Sports Med. 2021;55(7):356–368. [bjsm.bmj.com] Janse van Rensburg DC, Fowler PM, Racinais S. Practical tips to manage travel fatigue and jet lag in athletes. Br J Sports Med. 2021;55(15):821–822. [bjsm.bmj.com] Watson NF, Badr MS, Belenky G, et al. Recommended amount of sleep for a healthy adult: AASM/SRS consensus statement. Sleep. 2015;38(6):843–844. [aasm.org] Centers for Disease Control and Prevention. FastStats: Sleep in adults. CDC. 2024. Available from: https://www.cdc.gov/sleep/… [cdc.gov]
References: Gooley JJ, Chamberlain K, Smith KA, et al. Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans. J Clin Endocrinol Metab. 2011;96(3):E463‑E472. [academic.oup.com] Chang AM, Aeschbach D, Duffy JF, Czeisler CA. Evening use of light‑emitting eReaders negatively affects sleep, circadian timing, and next‑morning alertness. Proc Natl Acad Sci USA. 2015;112(4):1232‑1237. [hms.harvard.edu] Schöllhorn I, Stefani O, Lucas RJ, et al. Melanopic irradiance defines the impact of evening display light on sleep latency, melatonin and alertness. Commun Biol. 2023;6:1090. [nature.com] He J‑W, Tu Z‑H, Xiao L, Su T, Tang Y‑X. Effect of restricting bedtime mobile phone use on sleep, arousal, mood, and working memory: A randomized pilot trial. PLoS One. 2020;15(2):e0228756. [journals.plos.org] Hartstein LE, Mathew GM, Reichenberger DA, et al. The impact of screen use on sleep health across the lifespan: a National Sleep Foundation consensus statement. Sleep Health. 2024;10(4):373‑384. [sleephealt…ournal.org] Höhn C, Hahn MA, Gruber G, et al. Effects of evening smartphone use on sleep and declarative memory consolidation in male adolescents and young adults. Brain Commun. 2024;6(3):fcae173. Finucane E, O’Brien A, Treweek S, et al. Does reading a book in bed make a difference to sleep? The People’s Trial—an online, pragmatic randomized trial. Trials. 2021;22:873. [link.springer.com] Ong JC, Manber R, Segal Z, Xia Y, Shapiro S, Wyatt JK. A randomized controlled trial of mindfulness meditation for chronic insomnia. Sleep. 2014;37(9):1553‑1563. [academic.oup.com] , [mindfulchair.com] He X, Pan B, Ma N, et al. The association of screen time and the risk of sleep outcomes: a systematic review and meta‑analysis. Front Psychiatry. 2025;16:1640263. Shechter A, Quispe KA, Mizhquiri Barbecho JS, et al. Interventions to reduce short‑wavelength light at night and their effects on sleep: systematic review and meta‑analysis. SLEEP Advances. 2020;1(1):zpaa002. [academic.oup.com]
References: Harkin B, Webb TL, Chang BPI, Prestwich A, Conner M, Kellar I, et al. Does monitoring goal progress promote goal attainment? A meta-analysis of the experimental evidence. Psychol Bull . 2016;142(2):198–229. Available from: https://www.apa.org/pubs/journals/releases/bul-bul0000025.pdf Compernolle S, DeSmet A, Poppe L, Crombez G, De Bourdeaudhuij I, Cardon G, et al. Effectiveness of interventions using self-monitoring to reduce sedentary behavior in adults: a systematic review and meta-analysis. Int J Behav Nutr Phys Act . 2019;16(1):63. Available from: https://link.springer.com/article/10.1186/s12966-019-0824-3 Patel ML, Brooks TL, Bennett GG. Consistent self‑monitoring in a commercial app‑based intervention for weight loss: results from a randomized trial. J Behav Med . 2020;43:391–401. Available from: https://link.springer.com/article/10.1007/s10865-019-00091-8 Patel ML, Hopkins CM, Brooks TL, Bennett GG. Comparing self-monitoring strategies for weight loss in a smartphone app: randomized controlled trial. JMIR Mhealth Uhealth . 2019;7(2):e12209. Available from: https://mhealth.jmir.org/2019/2/e12209/ Lally P, Van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. Available from: https://repositorio.ispa.pt/bitstream/10400.12/3364/1/IJSP_998-1009.pdf Singh B, Murphy A, Maher C, Smith AE. Time to form a habit: A systematic review and meta-analysis of health behaviour habit formation and its determinants. Healthcare (Basel) . 2024;12(23):2488. Available from: https://www.mdpi.com/2227-9032/12/23/2488 Gollwitzer PM, Sheeran P. Implementation intentions and goal achievement: A meta‑analysis of effects and processes. In: Advances in Experimental Social Psychology . 2006;38:69–119. Available from: https://www.researchgate.net/publication/37367696 Adriaanse MA, Gollwitzer PM, De Ridder DTD, De Wit JBF, Kroese FM. Breaking habits with implementation intentions: A test of underlying processes. Pers Soc Psychol Bull . 2011;37(4):502–13. Available from: https://dspace.library.uu.nl/bitstream/handle/1874/380229/0146167211399102.pdf Palmer CA, Bower JL, Cho KW, Clementi MA, Lau S, Oosterhoff B, et al. Sleep loss and emotion: A systematic review and meta-analysis of over 50 years of experimental research. Psychol Bull . 2023;149(11):2314–48. Available from: https://www.apa.org/pubs/journals/releases/bul-bul0000410.pdf Kong Y, Yu B, Guan G, Wang Y, He H. Effects of sleep deprivation on sports performance and perceived exertion in athletes and non-athletes: a systematic review and meta-analysis. Front Physiol . 2025;16:1544286. Available from: https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2025.1544286/full Tadros M, Newby JM, Li S, Werner‑Seidler A. Psychological treatments to improve sleep quality in university students: systematic review and meta-analysis. PLoS One . 2025;20(2):e0317125. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0317125 Locke EA, Latham GP. Building a practically useful theory of goal setting and task motivation: A 35‑year odyssey. Am Psychol . 2002;57(9):705–17. Available from: https://med.stanford.edu/content/dam/sm/s-spire/documents/PD.locke-and-latham-retrospective_Paper.pdf
Reference: ACRP. “ICH E6(R2) to ICH E6(R3) Comparison.” (Jan 28, 2025) — terminology & essential records: PDF Clinical Trials Toolkit. “Summary of Key Changes in ICH E6(R3).” (Mar 25, 2025) — proportionality, QbD, safety reporting: Article PharmaEduCenter. “Key changes between ICH GCP E6 R3 and E6 R2.” (Aug 10, 2025) — structure & glossary: Blog CITI Program. “Navigating the Transition from ICH E6(R2) to ICH E6(R3).” (Mar 12, 2025) — consent & site practices: Blog IntuitionLabs. “ICH E6 (R3) Explained.” (Updated Jan 13, 2026) — rationale, data governance: Deep dive
Simplify your day with essentialism: set priorities, eliminate the non‑essential, time‑block deep work, and measure progress for stress‑free productivity.
A runner’s guide to VO₂ max: why plateaus happen and how to fix them with long intervals, tempo, hills, cross‑training and smart periodization.